Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations: Proceedings from the Alzheimer's Association Research Roundtable (AARR) Fall 2021 meeting

Abstract The design of clinical trials in Alzheimer's disease (AD) must consider the development of new plasma, cerebrospinal fluid (CSF), and imaging biomarkers. They must also define clinically meaningful outcomes for patients and set endpoints that measure these outcomes accurately. With the acce...

Ful tanımlama

Detaylı Bibliyografya

Asıl Yazarlar:	Ronald C. Petersen, Ana Graf, Chris Brady, Susan De Santi, Hana Florian, Jaren Landen, Mike Pontecorvo, Christopher Randolph, Kaycee Sink, Maria Carrillo, Christopher J. Weber
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Wiley 2025-01-01
Seri Bilgileri:	Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Konular:	Alzheimer disease amyloid biomarkers clinical trial cognition cognitive impairment
Online Erişim:	https://doi.org/10.1002/trc2.70038
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!